antisynthetase syndrome
Information
- Disease name
- antisynthetase syndrome
- Disease ID
- DOID:0080744
- Description
- "An autoimmune disease that is characterized by myositis, arthralgia, Raynaud phenomenon, mechanic hands, interstitial lung disease, and serum autoantibodies to aminoacyl transfer RNA synthetases." [url:https\://en.wikipedia.org/wiki/Antisynthetase_syndrome, url:https\://pubmed.ncbi.nlm.nih.gov/27594777/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05691725 | Completed | Evaluation of Peripheral Neutrophils in Antisynthetase Syndrome | February 1, 2023 | April 1, 2023 | |
| NCT05984394 | Not yet recruiting | Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease | October 31, 2023 | October 31, 2025 | |
| NCT05989399 | Not yet recruiting | Evaluation of Circulating Neutrophils in Antisynthetase Syndrome | January 1, 2024 | October 31, 2025 | |
| NCT05832034 | Recruiting | Phase 2 | Add-on Intravenous Immunoglobulins in Early Myositis | September 13, 2021 | September 2024 |
| NCT05523167 | Recruiting | Phase 2/Phase 3 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. | October 12, 2022 | February 1, 2027 |
| NCT05979441 | Recruiting | Phase 3 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | September 12, 2023 | September 2027 |
| NCT04924465 | Unknown status | Evaluation of Interstitial Lung Disease Severity in Patients With Antisynthetase Syndrome According to Specific Autoantibodies Profile | June 2021 | December 2023 | |
| NCT04941547 | Unknown status | Association Between Cancer and Anti-synthetase Syndrome | April 1, 2021 | September 1, 2021 |
- Disase is a (Disease Ontology)
- DOID:417
- Cross Reference ID (Disease Ontology)
- GARD:735
- Cross Reference ID (Disease Ontology)
- MESH:C537778
- Cross Reference ID (Disease Ontology)
- ORDO:81
- OrphaNumber from OrphaNet (Orphanet)
- 81